How many clinical trials are studying Radium-223?

3 recruiting trials in our tracked data involve Radium-223.

What conditions is Radium-223 being studied for?

In our tracked recruiting trials, Radium-223 is being studied in trials for Prostate Cancer, Advanced Cancer, Castration-resistant.

Yes. According to the FDA drug label available through openFDA, Radium-223 is an FDA-approved drug.

Recruiting trials

Conditions studied

US states with sites

Countries

FDA-approved: Yes. Radium-223 appears in the FDA drug-label database. Marketed as Radium bromatum.

Uses: See symptoms on front panel. Relieves itching with burning sensation improved by scratching *

Phase 2 1 Phase 3 1 Not applicable 1

Condition	Trials
Prostate Cancer · Radium-223 for Prostate Cancer	3
Advanced Cancer	1
Castration-resistant	1
Metastatic Castration-resistant Prostate Cancer	1
Metastatic Prostate Adenocarcinoma	1
Prostate Adenocarcinoma	1

Yes, marketed as Radium bromatum.

3 recruiting trials across 6 conditions.

No. For the full record, search ClinicalTrials.gov.